logo
logo
AZTA stock ticker logo

Azenta, Inc.

NASDAQ•AZTA
CEO: Mr. John P. Marotta
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1995-02-02
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates through three reportable segments: Sample Management Solutions, Multiomics, and B Medical Systems. The Sample Management Solutions segment provides sample management products and solutions, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, synthesis editing, and related services. The B Medical Systems segment manufactures and distributes temperature-controlled storage and transportation solutions to governments, health institutions, and non-government organizations. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Contact Information
200 Summit Drive, 6th Floor, Burlington, MA, 01803, United States
888-229-3682
www.azenta.com
Market Cap
$1.15B
P/E (TTM)
-19.9
57.7
Dividend Yield
--
52W High
$41.73
52W Low
$19.87
52W Range
24%
Rank45Top 56.8%
3.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q1 2026 Data

Revenue

$148.64M+0.00%
4-Quarter Trend

EPS

-$0.34+0.00%
4-Quarter Trend

FCF

$14.66M+0.00%
4-Quarter Trend

2026 Q1 Earnings Highlights

Key Highlights

Total Revenue Modest Growth Total revenue reached $148.6M for the quarter, marking a 0.8% increase over prior year period.
SG&A Expenses Reduced Selling, general, administrative expenses totaled $60.6M, decreasing $9.4M due to lower compensation and one-time costs.
R&D Investment Increased Research and development expenses rose to $9.2M, reflecting a $2.1M increase supporting new product introductions.
Strong Liquidity Position Total cash, restricted cash, and marketable securities stood at $571.0M at period end, supporting operations for over one year.

Risk Factors

Gross Margin Declined Sharply Gross margin fell to 42.9% from 46.7%, driven by rework costs and lost cost leverage in Multiomics segment.
Discontinued Loss Widened Loss from discontinued operations increased to $(10.2)M, primarily due to a $9.7M loss on assets held for sale.
Internal Control Deficiencies Persist Material weaknesses in cash flow review, reconciliations, and expense classification remain outstanding as of December 31, 2025.
B Medical Sale Financing Risk Completion of B Medical sale hinges on Thelema securing $54.0M financing by March 31, 2026, posing completion uncertainty.

Outlook

Finalizing B Medical Sale Strategic divestiture of B Medical Systems aims to simplify portfolio and focus management on core SMS and Multiomics segments.
New Share Repurchase Authorized Board approved a new $250M share repurchase program through December 31, 2028; no repurchases executed yet.
Continued Product Development Focus Expect continued investment in R&D to support new product introduction and enhance existing offerings across core businesses.
Remaining Performance Obligations $70.0M in remaining performance obligations expected to convert to revenue over the next one year and beyond.

Peer Comparison

Revenue (TTM)

TDOC stock ticker logoTDOC
$2.53B
-1.5%
EVO stock ticker logoEVO
$886.93M
-1.4%
NEOG stock ticker logoNEOG
$870.54M
-3.9%

Gross Margin (Latest Quarter)

ATAI stock ticker logoATAI
100.0%
+0.0pp
NVCR stock ticker logoNVCR
75.8%
-3.9pp
STAA stock ticker logoSTAA
73.4%
+17.6pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
SYRE$4.41B-162.8-29.4%0.0%
TXG$3.33B-76.1-5.7%15.1%
NEOG$2.07B-3.4-29.0%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.2%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow

Deep Research

Next earnings:May 5, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data